Vuity Consultation

Vuity Consultation

Vuity Consultation

VUITY (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available

  • Presbyopia, or age-related blurry near vision, is a common, progressive condition that reduces the eye's ability to focus on near objects and affects nearly half of the U.S. adult population, usually over age 40

  • VUITY is a once-daily prescription eye drop that improves near and intermediate vision without impacting distance vision for adults with age-related blurry near vision


NORTH CHICAGO, Ill., December 9, 2021 – Allergan, an AbbVie (NYSE: ABBV) company, today announced that VUITY (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the U.S. Food and Drug Administration (FDA) to treat presbyopia, is now available by prescription in pharmacies nationwide. Presbyopia, or age-related blurry near vision, can be diagnosed through a basic eye exam by an eye doctor (optometrist or ophthalmologist) and is a common and progressive eye condition that affects 128 million Americans, or nearly half of the U.S. adult population.


“We are pleased to be able to bring this first-of-its-kind treatment to market sooner than expected for the millions of Americans with presbyopia who may benefit from it,” said Jag Dosanjh, senior vice president medical therapeutics, Allergan, an AbbVie company. “This significant innovation in age-related eye health reflects our commitment to advance vision care and expands our leading portfolio of treatments for eye care providers and their patients.”


“Many Americans deal with presbyopia, which typically begins around age 40, by relying on reading glasses or resorting to work-arounds like zooming in on their digital devices to see up close. As an optometrist who also has presbyopia, I'm personally and professionally excited to try VUITY for myself, as well as offer it to my patients with age-related blurry near vision,” said optometrist Dr. Selina McGee, Fellow of the American Academy of Optometry. “With VUITY now available, it is a good time for those who experience age-related blurry near vision to visit their eye doctor for an exam and to discuss their options to manage this common condition.”


VUITY is an optimized formulation of pilocarpine, an established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHast™ technology, which allows VUITY to rapidly adjust to the physiologic pH of the tear film. This was studied in simulated tear film, and the clinical significance is unknown. VUITY uses the eye’s own ability to reduce pupil size, improving near and intermediate vision while maintaining distance vision.


“As I’ve gotten older, my vision has changed, and it has become almost impossible to see clearly up close unless I wear my readers. Realizing that I needed to start using readers showed me how important it was to address this condition,” said Toni Wright, clinical trial participant. “It was great to have the opportunity to participate in the clinical study investigating a new potential treatment option. I’m so excited the investigational treatment, which has been identified as VUITY, is now approved and available as a treatment to manage age-related blurry near vision.”


Click here to book your eye exam today to see if you are a candidate for Vuity


About the VUITY Clinical Development Program

The FDA approval of VUITY in October 2021 was based on data from two pivotal phase 3 clinical studies, GEMINI 1 and GEMINI 2, which evaluated the efficacy, safety and tolerability of VUITY for the treatment of presbyopia.

  • A total of 750 participants aged 40 to 55 years old with presbyopia were randomized in the two studies in a one-to-one ratio to either VUITY or placebo.

  • Participants were instructed to administer one drop of VUITY or placebo once daily in each eye.

  • Both studies met their primary endpoints with a statistically significant proportion of participants treated with VUITY gaining three lines (the ability to read three additional lines on a reading chart) or more in mesopic (in low light), high contrast, binocular Distance Corrected Near Visual Acuity (DCNVA), without losing more than 1 line (5 letters) of Corrected Distance Visual Acuity (CDVA) at day 30, hour 3, versus placebo.

  • There were no serious adverse events observed in any participants treated with VUITY in either clinical study. The most common adverse events occurring at a frequency of >5% in participants treated with VUITY were headache and eye redness.

About Presbyopia

Presbyopia, known as age-related blurry near vision, is a common and progressive eye condition that reduces the eye’s ability to focus on near objects and usually impacts people after age 40. In a non-presbyopic eye, the clear lens behind the iris can change shape and focus light to the retina, making it easier to see things up close. In a presbyopic eye, the clear lens hardens and does not change shape as easily, making it difficult to focus on near objects. Presbyopia can be diagnosed by an eye doctor (ophthalmologist/optometrist).

Approved Use and Important Safety Information

USE

VUITY™ (pilocarpine hydrochloride ophthalmic solution) 1.25% is a prescription eye drop used to treat age-related blurry near vision (presbyopia) in adults.

IMPORTANT SAFETY INFORMATION

  • Do not use VUITY if you are allergic to any of the ingredients.

  • Use caution when driving at night or performing hazardous activities in poor lighting.

  • Temporary problems when changing focus between near and distant objects may occur. Do not drive or use machinery if vision is not clear.

  • Seek immediate medical care if you experience any sudden vision loss.

  • If you wear contact lenses, they should be removed prior to VUITY use. Wait 10 minutes after dosing before reinserting contact lenses.

  • Do not touch the dropper tip to any surface as this may contaminate the contents.

  • If more than one topical eye medication is being used, they must be administered at least 5 minutes apart.

  • The most common side effects are headaches and eye redness. These are not all the possible side effects of VUITY.

mamadjoon:) none 10:00 AM - 7:00 PM 10:00 AM - 7:00 PM 8:00 AM - 5:00 PM 8:00 AM - 5:00 PM 8:00 AM - 5:00 PM 9:00 AM - 2:00 PM 11:00AM - 2:00PM Walk-ins WelcomeSunday By Appointment Only optometrist https://g.page/r/CQTnIX_sk9piEAI/review https://www.yelp.com/writeareview/biz/4qgb1ltuTxl-GQOYJHBr3w?return_url=%2Fbiz%2F4qgb1ltuTxl-GQOYJHBr3w&source=biz_details_war_button https://www.facebook.com/heightseyestudio/reviews/?ref=page_internal https://www.4patientcare.ws/v5dn/ws/wsv3p.aspx?CoverKey=5395&TaskKey=126868&LocKey=13543&V4Scenario=3&Source=website&ReferredBy=website